Unresectable hepatocellular carcinoma in cirrhosis
Abstract To evaluate the efficacy of transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma, the prognostic factors, and the side effects, 72 patients undergoing 170 chemoembolizations with lipiodol-mediated injection of adriamycin were investigated. The 1-, 2-, and 3-year survivals are 83, 61, and 56%, respectively. Significant prognostic factors for survival (by Mantael-Haenszel) are Child-Pugh and Okuda status (p=0.00001 and p=0.01 respectively), number of TACE courses (p=0.002) and of courses completed with embolization (p=0.05), stabilization or reduction of α-fetoprotein (p=0.003), and concurrent tamoxifen treatment (p=0.04). Side effects included fever, pain, increased serum amylase and transaminase levels, and one liver abscess with death of liver failure. In addition, mild hyperglycemia was observed in 19% of patients and severe in 8% (with one hyperosmolar diabetic coma), in the absence of pancreatic damage. In conclusion, transcatheter arterial chemoembolization is useful in patients with unresectable hepatocellular carcinoma. Prognostic factors are Child-Pugh and Okuda status, number of TACE courses and of embolizations, changes of α-fetoprotein levels, and association with tamoxifen treatment. The development of mild to severe changes of glucose metabolism suggests that glucose tolerance should be evaluated before and glycemia strictly monitored after each TACE course..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
1996 |
---|---|
Erschienen: |
1996 |
Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
---|---|
Enthalten in: |
Digestive diseases and sciences - 41(1996), 12 vom: Dez., Seite 2332-2339 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Farinati, Fabio [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Anmerkungen: |
© Plenum Publishing Corporation 1996 |
---|
doi: |
10.1007/BF02100123 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2027160051 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | OLC2027160051 | ||
003 | DE-627 | ||
005 | 20230518170727.0 | ||
007 | tu | ||
008 | 200819s1996 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1007/BF02100123 |2 doi | |
035 | |a (DE-627)OLC2027160051 | ||
035 | |a (DE-He213)BF02100123-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
100 | 1 | |a Farinati, Fabio |e verfasserin |4 aut | |
245 | 1 | 0 | |a Unresectable hepatocellular carcinoma in cirrhosis |
264 | 1 | |c 1996 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © Plenum Publishing Corporation 1996 | ||
520 | |a Abstract To evaluate the efficacy of transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma, the prognostic factors, and the side effects, 72 patients undergoing 170 chemoembolizations with lipiodol-mediated injection of adriamycin were investigated. The 1-, 2-, and 3-year survivals are 83, 61, and 56%, respectively. Significant prognostic factors for survival (by Mantael-Haenszel) are Child-Pugh and Okuda status (p=0.00001 and p=0.01 respectively), number of TACE courses (p=0.002) and of courses completed with embolization (p=0.05), stabilization or reduction of α-fetoprotein (p=0.003), and concurrent tamoxifen treatment (p=0.04). Side effects included fever, pain, increased serum amylase and transaminase levels, and one liver abscess with death of liver failure. In addition, mild hyperglycemia was observed in 19% of patients and severe in 8% (with one hyperosmolar diabetic coma), in the absence of pancreatic damage. In conclusion, transcatheter arterial chemoembolization is useful in patients with unresectable hepatocellular carcinoma. Prognostic factors are Child-Pugh and Okuda status, number of TACE courses and of embolizations, changes of α-fetoprotein levels, and association with tamoxifen treatment. The development of mild to severe changes of glucose metabolism suggests that glucose tolerance should be evaluated before and glycemia strictly monitored after each TACE course. | ||
700 | 1 | |a De Maria, Nicola |4 aut | |
700 | 1 | |a Marafin, Cinzia |4 aut | |
700 | 1 | |a Herszènyi, Làszlò |4 aut | |
700 | 1 | |a Prato, Stefano Del |4 aut | |
700 | 1 | |a Rinaldi, Michela |4 aut | |
700 | 1 | |a Perini, Luciano |4 aut | |
700 | 1 | |a Cardin, Romilda |4 aut | |
700 | 1 | |a Naccarato, Remo |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Digestive diseases and sciences |d Kluwer Academic Publishers-Plenum Publishers, 1979 |g 41(1996), 12 vom: Dez., Seite 2332-2339 |w (DE-627)129894036 |w (DE-600)304250-9 |w (DE-576)015213218 |x 0163-2116 |7 nnns |
773 | 1 | 8 | |g volume:41 |g year:1996 |g number:12 |g month:12 |g pages:2332-2339 |
856 | 4 | 1 | |u https://doi.org/10.1007/BF02100123 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OLC-DE-84 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_101 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2012 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4028 | ||
912 | |a GBV_ILN_4082 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4219 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4314 | ||
951 | |a AR | ||
952 | |d 41 |j 1996 |e 12 |c 12 |h 2332-2339 |